BH.IMMUN&BIO | IND. SWIFT | BH.IMMUN&BIO/ IND. SWIFT |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | 4.5 | - | View Chart |
P/BV | x | 1.5 | - | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BH.IMMUN&BIO IND. SWIFT |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
IND. SWIFT Mar-23 |
BH.IMMUN&BIO/ IND. SWIFT |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 15 | 354.1% | |
Low | Rs | 21 | 7 | 315.4% | |
Sales per share (Unadj.) | Rs | 10.3 | 75.9 | 13.6% | |
Earnings per share (Unadj.) | Rs | -3.9 | 4.8 | -80.2% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 10.1 | -37.7% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | -130.1 | -15.7% | |
Shares outstanding (eoy) | m | 43.18 | 54.16 | 79.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 0.1 | 2,512.9% | |
Avg P/E ratio | x | -9.4 | 2.2 | -426.8% | |
P/CF ratio (eoy) | x | -9.5 | 1.0 | -907.7% | |
Price / Book Value ratio | x | 1.8 | -0.1 | -2,179.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 572 | 272.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 637 | 23.8% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 4,110 | 10.9% | |
Other income | Rs m | 11 | 119 | 8.9% | |
Total revenues | Rs m | 457 | 4,228 | 10.8% | |
Gross profit | Rs m | -161 | 1,026 | -15.7% | |
Depreciation | Rs m | 2 | 287 | 0.7% | |
Interest | Rs m | 71 | 598 | 11.8% | |
Profit before tax | Rs m | -223 | 260 | -85.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 0 | - | |
Profit after tax | Rs m | -166 | 260 | -63.9% | |
Gross profit margin | % | -36.0 | 25.0 | -144.3% | |
Effective tax rate | % | 25.3 | 0 | - | |
Net profit margin | % | -37.3 | 6.3 | -588.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 2,734 | 13.1% | |
Current liabilities | Rs m | 940 | 9,363 | 10.0% | |
Net working cap to sales | % | -130.6 | -161.3 | 80.9% | |
Current ratio | x | 0.4 | 0.3 | 130.4% | |
Inventory Days | Days | 85 | 115 | 74.2% | |
Debtors Days | Days | 1,135 | 929 | 122.2% | |
Net fixed assets | Rs m | 1,262 | 3,758 | 33.6% | |
Share capital | Rs m | 432 | 108 | 398.6% | |
"Free" reserves | Rs m | 450 | -7,155 | -6.3% | |
Net worth | Rs m | 882 | -7,047 | -12.5% | |
Long term debt | Rs m | 0 | 4,031 | 0.0% | |
Total assets | Rs m | 1,620 | 6,492 | 25.0% | |
Interest coverage | x | -2.2 | 1.4 | -150.0% | |
Debt to equity ratio | x | 0 | -0.6 | -0.0% | |
Sales to assets ratio | x | 0.3 | 0.6 | 43.5% | |
Return on assets | % | -5.9 | 13.2 | -44.7% | |
Return on equity | % | -18.9 | -3.7 | 510.5% | |
Return on capital | % | -17.2 | -28.4 | 60.6% | |
Exports to sales | % | 0 | 68.8 | 0.0% | |
Imports to sales | % | 14.5 | 5.3 | 273.7% | |
Exports (fob) | Rs m | NA | 2,827 | 0.0% | |
Imports (cif) | Rs m | 65 | 217 | 29.7% | |
Fx inflow | Rs m | 0 | 2,947 | 0.0% | |
Fx outflow | Rs m | 65 | 313 | 20.6% | |
Net fx | Rs m | -65 | 2,634 | -2.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 730 | 14.9% | |
From Investments | Rs m | 5 | -293 | -1.6% | |
From Financial Activity | Rs m | -147 | -466 | 31.6% | |
Net Cashflow | Rs m | -34 | -29 | 117.6% |
Indian Promoters | % | 59.3 | 55.6 | 106.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 44.4 | 91.7% | |
Shareholders | 35,313 | 16,438 | 214.8% | ||
Pledged promoter(s) holding | % | 0.0 | 42.8 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | IND. SWIFT | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | -1.96% | 0.31% |
1-Month | -2.23% | 31.18% | 0.08% |
1-Year | 28.97% | 186.78% | 54.11% |
3-Year CAGR | -13.27% | 79.42% | 14.46% |
5-Year CAGR | 30.36% | 39.64% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the IND. SWIFT share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of IND. SWIFT the stake stands at 55.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of IND. SWIFT.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
IND. SWIFT paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of IND. SWIFT.
For a sector overview, read our pharmaceuticals sector report.
Indian share markets continued the momentum as the session progressed and ended higher.